Melanoma

Facial Plastic Surgery Clinics of North America

Volumn 21, Issue 1, 2013, Pages 33-42

  Ingraffea, Adam ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

BRAF; Immunotherapy; Melanoma; Noninvasive imaging; Skin cancer

Indexed keywords

ALPHA INTERFERON; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 7; IPILIMUMAB; TEMOZOLOMIDE; VEMURAFENIB;

ABDOMINAL PAIN; ACTINIC KERATOSIS; ALOPECIA; ARTHRALGIA; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER STAGING; CANCER SURVIVAL; CONGENITAL NEVUS; CUTANEOUS MELANOMA; DERMATITIS; DESMOPLASTIC MELANOMA; DIAGNOSTIC ACCURACY; DIARRHEA; DRUG ERUPTION; DYSPLASTIC NEVUS; ENDOCRINE DISEASE; ENTEROCOLITIS; ENVIRONMENTAL EXPOSURE; FAMILY HISTORY; FATIGUE; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HEALTH CARE QUALITY; HEPATITIS; HUMAN; KERATOACANTHOMA; LONG TERM EXPOSURE; LYMPH NODE DISSECTION; MALIGNANT LENTIGO; MELANOCYTIC NEVUS; MELANOGENESIS; MELANOMA; NAUSEA; NEUROPATHY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; REVIEW; RISK FACTOR; SEBORRHEIC KERATOSIS; SUN EXPOSURE; SURVIVAL RATE; TOXIC EPIDERMAL NECROLYSIS; VITILIGO; VOMITING;

HUMANS; INCIDENCE; MELANOMA; NEOPLASM STAGING; RISK FACTORS; SKIN NEOPLASMS;

EID: 84873814479     PISSN: 10647406     EISSN: 15581926     Source Type: Journal    
DOI: 10.1016/j.fsc.2012.11.007     Document Type: Review

References (62)

1. Erdei E., Torres S.M. A new understanding in the epidemiology of melanoma. Expert Rev Anticancer Ther 2010, 10(11):1811-1823.
2. Melanoma. National Cancer Institute. Available at: Accessed September 17, 2012. http://www.cancer.gov/cancertopics/types/melanoma.
3. Melanoma. Available at: Accessed August 24, 2012. http://nci.nih.gov/aboutnci/servingpeople/snapshots/melanoma.pdf.
4. Jemal A., Devesa S.S., Hartge P., et al. Recent trends in melanoma incidence among whites in the United States. J Natl Cancer Inst 2001, 93:678-683.
5. Eide M.J., Weinstock M.A. Association of UV index, latitude, and melanoma incidence in nonwhite populations: US Surveillance, Epidemiology, and End Results (SEER) Program, 1992-2001. Arch Dermatol 2005, 141(4):477-481.
6. Melanoma. Available at: Accessed March 19, 2012. http://www.cdc.gov/cancer/dcpc/research/articles/melanoma_supplement.htm.
7. Hu S., Parmet Y., Allen G., et al. Disparity in melanoma: a trend analysis of melanoma incidence and stage at diagnosis among whites, Hispanics, and blacks in Florida. Arch Dermatol 2009, 145(12):1369-1374.
8. Clark L.N., Shin D.B., Troxel A.B., et al. Association between the anatomic distribution of melanoma and sex. J Am Acad Dermatol 2007, 56:768-773.
9. Chang Y.M., Barrett J.H., Bishop D.T., et al. Sun exposure and melanoma risk at different latitudes: a pooled analysis of 5700 cases and 7216 controls. Int J Epidemiol 2009, 38:814-830.
10. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58(2):71-96.
11. Zito C.R., Kluger H.M. Immunotherapy for metastatic melanoma. J Cell Biochem 2012, 113(3):725-734.
12. Houghton A.N., Polsky D. Focus on melanoma. Cancer Cell 2002, 2(4):275-278.
13. Thompson J.F., Morton D.L., Kroon B.B. Textbook of melanoma 2004, Martin Dunitz, London.
14. Goldstein A.M., Struewing J.P., Chidambaram A., et al. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst 2000, 92:1006-1010.
15. Jemal A., Siegel R., Xu J., et al. Cancer statistics, 2010. CA Cancer J Clin 2010, 60(5):277-300.
16. Scolyer R.A., Long G.V., Thompson J.F. Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. Mol Oncol 2011, 5(2):124-136.
17. High W.A., Robinson W.A. Genetic mutations involved in melanoma: a summary of our current understanding. Adv Dermatol 2007, 23:61-79.
18. Kraemer K.H., et al. The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. The xeroderma pigmentosum paradigm. Arch Dermatol 1994, 130:1018-1021.
19. Easton D. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999, 91:1310-1316.
20. Psaty E.L., Scope A., Halpern A.C., et al. Defining the patient at high risk for melanoma. Int J Dermatol 2010, 49(4):362-376.
21. Ferrone C.R., et al. Clinicopathological features of and risk factors for multiple primary melanomas. JAMA 2005, 294:1647-1654.
22. Stam-Postguna J.J., et al. Multiple primary melanomas. J Am Acad Dermatol 2001, 44:22-27.
23. Gandini S., et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 2005, 41:2040-2059.
24. Hemminki K., Zhang H., Czene K. Familial and attributable risks in cutaneous melanoma: effects of proband and age. J Invest Dermatol 2003, 120:217-223.
25. Jemal A., Thun M.J., Ries L.A., et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008, 100(23):1672-1694.
26. Levi F., et al. Non-Hodgkin's lymphomas, chronic lymphocytic leukaemias and skin cancers. Br J Cancer 1996, 74:1847-1850.
27. Euvrard S., Kanitakis J., Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003, 348:1681-1691.
28. Wei-Passanese E.X., Han J., Lin W., et al. Geographical variation in residence and risk of multiple non-melanoma skin cancers in US women and men. Photochem Photobiol 2012, 88:483-489.
29. Goldberg M.S., et al. Risk factors for presumptive melanoma in skin cancer screening: American Academy of Dermatology National Melanoma/Skin Cancer Screening program experience 2001-2005. J Am Acad Dermatol 2007, 57:60-66.
30. Goodson A.G., Grossman D. Strategies for early melanoma detection: approaches to the patient with nevi. J Am Acad Dermatol 2009, 60:719-735.
31. The International Agency for Research on Cancer Working Group on Artificial Ultraviolet (UV) Light, Skin Cancer The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: a systematic review. Int J Cancer 2007, 120:1116-1122.
32. Olsen C.M., Zens M.S., Stukel T.A., et al. Nevus density and melanoma risk in women: a pooled analysis to test the divergent pathway hypothesis. Int J Cancer 2009, 124(4):937-944.
33. Albert L.S., Sober A.J. The dysplastic nevus as precursor and marker of increased risk for melanoma. Cutaneous melanoma 1992, 60-69. Lippincott, Philadelphia. 2nd edition. C.M. Balch, A.N. Houghton, G.W. Milton (Eds.).
34. Price H.N., Schaffer J.V. Congenital melanocytic nevi: when to worry and how to treat. Facts and controversies. Clin Dermatol 2010, 28(3):293-302.
35. Hirokawa D., Lee J.B. Dermatoscopy: an overview of subsurface morphology. Clin Dermatol 2011, 29(5):557-565.
36. Murali R., Shaw H.M., Lai K., et al. Prognostic factors in cutaneous desmoplatic melanoma: a study of 252 patient. Cancer 2010, 116:4130-4138.
37. Chen J.Y., Hruby G., Scolyer R.A., et al. Desmoplastic neurotropic melanoma: a clinicopathologic analysis of 128 cases. Cancer 2008, 113:2770-2778.
38. Balch C.M., Gershenwald J.E., Soong S.J., et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27(36):6199-6206.
39. Bichakjian C.K., Halpern A.C., Johnson T.M., American Academy of Dermatology, et al. Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. J Am Acad Dermatol 2011, 65(5):1032-1047.
40. Geller A.C., Swetter S.M., Oliveria S., et al. Reducing mortality in individuals at high risk for advanced melanoma through education and screening. J Am Acad Dermatol 2011, 65(5 Suppl 1):S87-S94.
41. Swetter S.M., Pollitt R.A., Johnson T.M., et al. Behavioral determinants of successful early melanoma detection: role of self and physician skin examination. Cancer 2012, 118:3725-3734.
42. Haigh P., DiFronzo L., McCready D. Optimal excision margins for primary cutaneous melanoma: a systematic review and meta-analysis. Can J Surg 2003, 46:419-426.
43. Morton D.L., Thompson J.F., Cochran A.J., et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006, 355:1307-1317.
44. Fukada H., Hiratsuka J., Kobayashi T., et al. Boron neutron capture therapy (BNCT) for malignant melanoma with special reference to absorbed doses to the normal skin and tumor. Australas Phys Eng Sci Med 2003, 26(3):97-103.
45. Atkins M.B., Kunkel L., Sznol M., et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long term survival update. Cancer J Sci Am 2000, 6(Suppl 1):S11-S14.
46. Jilaveanu L.B., Aziz S.A., Kluger H.M. Chemotherapy and biologic therapies for melanoma: do they work?. Clin Dermatol 2009, 27(6):614-625.
47. Davis I.D., Brady B., Kefford R.F., et al. Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res 2009, 15(6):2123-2129.
48. Williams P., Rafei M., Bouchentouf M., et al. A fusion of GMCSF and IL-21 initiates hypersignaling through the IL-21R alpha chain with immune activating and tumoricidal effects in vivo. Mol Ther 2010, 18(7):1293-1301.
49. Szabolcs P., Moore M.A., Young J.W. Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-alpha. J Immunol 1995, 154(11):5851-5861.
50. Lawson D.H., Lee S.J., Tarhini A.A., et al. E4697: Phase III cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III-IV melanoma. J Clin Oncol 2010, 28:15s.
51. Weber R.W., O'Day S., Rose M., et al. Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma. J Clin Oncol 2005, 23(35):8992-9000.
52. Mansh M. Ipilimumab and cancer immunotherapy: a new hope for advanced stage melanoma. Yale J Biol Med 2011, 84(4):381-389.
53. Chapman P.B., Hauschild A., Rpbert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364(26):2507-2516.
54. Ribas A., Hauschild A., Kefford R., et al. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J Clin Oncol 2008, 26:15s.
55. Tarhini A.A., Cherian J., Moschos S.J., et al. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol 2012, 30(3):322-328.
56. MelaFind. Available at: Accessed July 2, 2012. http://www.melasciences.com.
57. Monheit G., Cognetta A.B., Ferris L., et al. The performance of MelaFind: a prospective multicenter study. Arch Dermatol 2011, 147(2):188-194.
58. Friedman R.J., Gutkowicz-Krusin D., Farber M.J., et al. The diagnostic performance of expert dermoscopists vs a computer-vision system on small-diameter melanomas. Arch Dermatol 2009, 144(4):476-482.
59. Kirwood J.M., Lee S., Moschos S.J., et al. Immunogenicity and antitumor effects of vaccination with peptide vaccine +/-granulocyte-monocyte colonocyte stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res 2009, 15:1443-1451.
60. Adams S., O'Neill D.W., Nonaka D., et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 2008, 181(1):776-784.
61. Bogunovic D., Manches O., Godefroy E., et al. TLR4 engagement during TLR3-induced pro-inflammatory signaling in dendritic cells promotes IL-10-mediated suppression of anti-tumor immunity. Cancer Res 2011, 71:5467-5476.
62. Kefford R.F., et al. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the Melanoma Genetics Consortium. J Clin Oncol 1999, 17:3245-3251.